Jasmin Elurbide, Leticia Colyn, M Ujue Latasa, Iker Uriarte, Stefano Mariani, Amaya Lopez-Pascual, Emiliana Valbuena, Borja Castello-Uribe, Robert Arnes-Benito, Elena Adan-Villaescusa, Luz A Martinez-Perez, Mikel Azkargorta, Felix Elortza, Hanghang Wu, Marcin Krawczyk, Kai Markus Schneider, Bruno Sangro, Luca Aldrighetti, Francesca Ratti, Andrea Casadei Gardini, Jose Jg Marin, Irene Amat, Jesus Urman, Maria Arechederra, Maria L Martinez-Chantar, Christian Trautwein, Meritxell Huch, Francisco Javier Cubero, Carmen Berasain, Maite G Fernandez-Barrena, Matias A Avila
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.
Gut, 74(1) 116-127 (2025)
Open Access PubMed Source Full Text
Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic strategies need to be identified.
@article{Elurbide8796,
author={Jasmin Elurbide, Leticia Colyn, M Ujue Latasa, Iker Uriarte, Stefano Mariani, Amaya Lopez-Pascual, Emiliana Valbuena, Borja Castello-Uribe, Robert Arnes-Benito, Elena Adan-Villaescusa, Luz A Martinez-Perez, Mikel Azkargorta, Felix Elortza, Hanghang Wu, Marcin Krawczyk, Kai Markus Schneider, Bruno Sangro, Luca Aldrighetti, Francesca Ratti, Andrea Casadei Gardini, Jose Jg Marin, Irene Amat, Jesus Urman, Maria Arechederra, Maria L Martinez-Chantar, Christian Trautwein, Meritxell Huch, Francisco Javier Cubero, Carmen Berasain, Maite G Fernandez-Barrena, Matias A Avila},
title={Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.},
journal ={Gut},
volume={74},
issue ={1},
pages={116--127},
year=2025
}